These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Bucillamine-associated membranous nephropathy in a patient with rheumatoid arthritis]. Kawano M; Nomura H; Iwainaka Y; Nakashima A; Koni I; Tofuku Y; Takeda R Nihon Jinzo Gakkai Shi; 1990 Jul; 32(7):817-21. PubMed ID: 2273598 [TBL] [Abstract][Full Text] [Related]
4. [Drug-induced renal disorders in patients with rheumatoid arthritis]. Nakano M; Nishi S; Ueno M; Saito T; Hasegawa H; Arakawa M Ryumachi; 1996 Oct; 36(5):775-82. PubMed ID: 8969558 [No Abstract] [Full Text] [Related]
5. Membranous glomerulonephritis in patients with rheumatoid arthritis. Yoshida A; Morozumi K; Takeda A; Koyama K; Oikawa T Clin Ther; 1994; 16(6):1000-6. PubMed ID: 7697679 [TBL] [Abstract][Full Text] [Related]
6. Outcome and treatment of bucillamine-induced nephropathy. Hoshino J; Ubara Y; Hara S; Suwabe T; Sawa N; Tagami T; Katori H; Takemoto F; Hara S; Takaichi K Nephron Clin Pract; 2006; 104(1):c15-9. PubMed ID: 16685139 [TBL] [Abstract][Full Text] [Related]
7. Clinical course of bucillamine-induced nephropathy in patients with rheumatoid arthritis. Obayashi M; Uzu T; Harada T; Yamato M; Takahara K; Yamauchi A Clin Exp Nephrol; 2003 Dec; 7(4):275-8. PubMed ID: 14712356 [TBL] [Abstract][Full Text] [Related]
8. Comparison of clinical effects of bucillamine between additive combination and single administration study in rheumatoid arthritis. Nobunaga M; Yasuda M Agents Actions Suppl; 1993; 44():105-9. PubMed ID: 8372720 [TBL] [Abstract][Full Text] [Related]
9. "Yellow nail syndrome" and rheumatoid arthritis. Ichikawa Y; Shimizu H; Arimori S Tokai J Exp Clin Med; 1991 Dec; 16(5-6):203-9. PubMed ID: 1820660 [TBL] [Abstract][Full Text] [Related]
11. A case of rapidly progressive glomerulonephritis associated with bucillamine-treated rheumatoid arthritis. Yoshida A; Morozumi K; Takeda A; Koyama K; Oikawa T; Fujinami T Am J Kidney Dis; 1992 Oct; 20(4):411-3. PubMed ID: 1415212 [No Abstract] [Full Text] [Related]
12. Drug eruption due to bucillamine. Kimura M; Kawada A Contact Dermatitis; 1998 Aug; 39(2):98-9. PubMed ID: 9746202 [No Abstract] [Full Text] [Related]
13. Yellow nail induced by bucillamine. Ishizaki C; Sueki H; Kohsokabe S; Nishida H Int J Dermatol; 1995 Jul; 34(7):493-4. PubMed ID: 7591416 [No Abstract] [Full Text] [Related]
14. [A case of rheumatoid arthritis associated with agranulocytosis during bucillamine treatment]. Negishi M; Yamazaki J; Hosaka M; Iwabuchi H; Matsuda A; Kanemitsu H; Hiramatsu K; Kaga S; Hashimoto M; Kasama T Ryumachi; 1994 Jun; 34(3):651-5. PubMed ID: 8052932 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathological findings of bucillamine-induced nephrotic syndrome in patients with rheumatoid arthritis. Yoshida A; Morozumi K; Suganuma T; Sugito K; Ikeda M; Oikawa T; Fujinami T; Takeda A; Koyama K Am J Nephrol; 1991; 11(4):284-8. PubMed ID: 1799186 [TBL] [Abstract][Full Text] [Related]
16. [A case of rheumatoid arthritis developing pemphigus-like skin lesion during treatment with bucillamine]. Amasaki Y; Sagawa A; Atsumi T; Jodo S; Nakabayashi T; Watanabe I; Mukai M; Fujisaku A; Nakagawa S; Kobayashi H Ryumachi; 1991 Oct; 31(5):528-34; discussion 531-3. PubMed ID: 1837388 [TBL] [Abstract][Full Text] [Related]
17. [Effect of non-steroidal anti-inflammatory agents on kidney function in patients with rheumatoid arthritis]. Dvorkin EB; Murav'ev IuV Revmatologiia (Mosk); 1991; (2):28-30. PubMed ID: 1925261 [No Abstract] [Full Text] [Related]